Project partners

Universite Pierre et Marie Curie (UPMC)

Paris, France
http://www.upmc.fr/fr/recherche/pole_4/pole_vie_et_sante/immunite_et_infection_umrs_945.html

One of the largest universities for science and medicine in Europe. UPMC contributes 3 teams to the CUTHIVAC project. The first team is led by the overall CUTHIVAC coordinator Dr Béhazine Combadière and has expertise in vaccinology across the skin and immune memory. The 2nd team is lead by Prof Brigitte Autran and has extensive experience in HIV immunology. The 3rd team is lead by Dr Bertrand Bellier which has broad experience in genetic vaccines.

University of Regensburg (UREG)

Regensburg, Germany
http://www.ralf-wagner.com/

Lead by Prof Wagner this team has world reknowned expertise in HIV vaccine development, in particular epitopes enriched HIV Gag-Pol antigens and virus like particles.

IRSICAIXA Foundation

Barcelona, Spain
http://www.irsicaixa.es/en/home

The IrsiCaixa Institute for AIDS Research is an international reference institute for AIDS research that aims to contribute to the improvement of the knowledge, prevention and treatments of this disease with the final objective of eradicating the AIDS epidemic.

The IrsiCaixa team consists of over 50 researchers who focus their activity on basic research to understand HIV infection mechanisms and to develop new therapies and vaccines. In addition, the institute participates in clinical studies to assess new therapeutic strategies and collaborates with developing countries in the global battle against this pandemic.

The ”la Caixa” Foundation and the Department of Health of the Government of Catalonia created IrsiCaixa in 1995 as a non-profit private foundation. It is located at the Germans Trias i Pujol Hospital of Badalona.

FIT Biotech Oy Ltd

Tampere, Finland
http://www.fitbiotech.com/index.html

This R&D company has developed a highly effective DNA plasmid, GTU® (Gene Transport Unit) which can be used in vaccine applications. The team is lead by Prof Mart Ustav , Prof of Biomedical Technology and Iona Stanescu, Head of HIV Vaccine Business Area.

CHARITE

Berlin, Germany
http://www.crcberlin.com/

The Clinical Research Centre for Hair and Skin Science (CHARITE) has expertise in hair and skin physiology, with particular focus on particle penetration and their potential use as drug carriers or vaccines. The team is lead by Prof Ulrike Blume-Peytavi and Dr Annika Vogt.

St George’s University of London (SGUL)

London, UK
http://www.sgul.ac.uk/hivproject/

The Dept of Cellular and Molecular Medicine (SGUL) is a leading clinical research unit in infection and immunity specialising in vaccine and mucosal immunology.

MRC Medical Research Council

London, UK
http://www.ctu.mrc.ac.uk

The clinical trials unit at the MRC is a centre of excellence for clinical trials, meta-analyses, and epidemiological studies. Dr Sheena McCormack and Dr Sarah Joseph will coordinate the prophylactic vaccine trial.

IMPACTA

Lima, Peru
http://www.impactaperu.org/Portal/default.aspx

IMPACTA is a NGO experienced in the development of multi-centric clinical trials in HIV and STDs. The clinical trials unit is lead by Dr Jorge Sanchez and has already succesfully completed seven HIV clinical trials.

CNRS Centre National de la Recherche Scientifique

Lyon, France
http://www.ibcp.fr

CNRS is a publicy funded research organisation and the IBCP is a joint unit shared with the University of Lyon. The team there lead by Dr Bernard Verrier has expertise in the generation of nanoparticle based immunogens.

INSERM Institut National de la Santé et de la Recherche Médicale

Paris, France
http://www.ccde.fr

Inserm U943 is a centre of excellence for the studies of patients living long term with HIV. Dr Dominique Costagliola and Dr Christine Katlama will coordinate the therapeutic clinical trial.

Instituto Nacional de Saúde INS

Maputo, Mozambique
www.ins.gov.mz

The INS is a branch of the Ministry of Health focusing on research on HIV. The team lead by Dr Ilesh Jani will help with the identification of novel HIV antigens in infected patients.

GENEART AG

Regensburg, Germany
http://www.geneart.com

Geneart AG is a leading producer of DNA vaccines. Lead by Dr Frank Notka the team will provide the best optimisation strategy for the desired expression system of the novel candidate vaccines.

NOVAMEN

Lyon, France
http://www.novamen.eu/

NOVAMEN offers to European research institutes and industrial groups a set of services that meet each clients specific needs. This includes the identification of collaborative research projects, clients R&D activities and project portfolio, proposal building that comply with the requirements from various funding bodies, as well as management both strategic and operational of cross-thematic, multinational and multicultural research projects.
NOVAMEN has developed in-depth expertise in strategic and operational management of joint research programs, with over 150 projects submitted to date to European funding programmes. Over two thirds of the projects submitted by NOVAMEN to the Research Framework Program passed the thresholds of the EC selection process (75% of them in the Health thematic). This success rate is three times higher than the European average. NOVAMEN manages around 20 European projects simultaneously, representing budgets from 2.5 to 50 million euros over periods of 2 to 5 years.

Imperial College London

London, UK
http://www1.imperial.ac.uk/medicine/people/r.shattock/

The research group directed by Prof Robin Shattock is working on the pathogenesis and transmission of HIV infection, with a particular emphasis on the development of prevention strategies applicable to the developing world.

ORVACS

Paris, France

Created in 2001, the non-profit research organization ORVACS (Objectif Recherche Vaccin Sida) began its work thanks in large part to the financial support from Madame Liliane Bettencourt and her Foundation. ORVACS is an international network of researchers in basic and clinical sciences from some of the most prestigious French, North American and European universities. The teams of researchers involved are internationally recognized and have extensive expertise in the field of HIV and AIDS research. Thanks to its own experience and qualified dedicated personnel, ORVACS is capable of assuming the development, regulatory affairs, management, study implementation, the clinical, immunological and virologic evaluations, safety monitoring and the quality of the clinical trials on an international scale.